

Kyprolis® (carfilzomib) (Intravenous)

-E-

Document Number: OHSU HEALTHSERVICES-0386

Last Review Date: 01/04/2024

Date of Origin: 01/07/2019

Dates Reviewed: 01/2019, 04/2019, 07/2019, 10/2019, 01/2020, 04/2020, 07/2020, 10/2020, 01/2021, 05/2021, 07/2021, 10/2021, 01/2022, 04/2022, 07/2022, 10/2022, 01/2023, 05/2023, 07/2023, 10/2023, 01/2024

I. Length of Authorization ^{1,5,21,27,32,36}

Coverage will be provided for 6 months and may be renewed (unless otherwise specified).

Multiple Myeloma

- Combination therapy with lenalidomide and dexamethasone is limited to eighteen (18) 28-day treatment cycles.
- Combination therapy with daratumumab, lenalidomide, and dexamethasone is limited to eight (8) 28-day treatment cycles.
- Combination therapy with lenalidomide as maintenance therapy is limited to a maximum of 2 years of treatment.

Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma

- Combination therapy with rituximab and dexamethasone (CaRD regimen) is limited to six (6) 21-day induction treatment cycles and eight (8) 56-day maintenance treatment cycles.

II. Dosing Limits

A. Quantity Limit (max daily dose) [NDC Unit]:

- Kyprolis 10 mg single-dose vial: 2 vials per 28-day cycle
- Kyprolis 30 mg single-dose vial: 1 vial per 28-day cycle
- Kyprolis 60 mg single-dose vial: 12 vials per 28-day cycle

B. Max Units (per dose and over time) [HCPCS Unit]:

a. Multiple Myeloma

- 720 billable units (720 mg) every 28 days

- **Systemic Light Chain Amyloidosis**
 - 480 billable units (480 mg) every 28 days
- **Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma**
 - 320 billable units (320 mg) every 21 days

III. Initial Approval Criteria ¹

Coverage is provided in the following conditions:

- Patient is at least 18 years of age; **AND**

Multiple Myeloma † ‡ § 1,2,7,9-11,13-17,19,20,22-29,32-37,39,40,2e,4e,8e,10e,34e,37e-39e

- Used as primary therapy for symptomatic disease; **AND**
 - Used in combination with daratumumab, lenalidomide, and dexamethasone (*transplant candidates ONLY*); **OR**
 - Used in combination with lenalidomide and dexamethasone; **OR**
 - Used in combination with dexamethasone and cyclophosphamide; **OR**
- Used for disease relapse after 6 months following primary induction therapy with the same regimen; **AND**
 - Used in combination with lenalidomide and dexamethasone; **OR**
 - Used in combination with dexamethasone and cyclophosphamide; **OR**
- Used for relapsed or refractory disease after 3 prior therapies; **AND**
 - Used in combination with bendamustine and dexamethasone; **OR**
- Used for previously treated relapsed, progressive, or refractory disease; **AND**
 - Used as a single agent †; **OR**
 - Used in combination with one of the following regimens:
 - Dexamethasone with or without lenalidomide †
 - Dexamethasone and daratumumab †
 - Dexamethasone and daratumumab and hyaluronidase-fihj †
 - Dexamethasone and cyclophosphamide
 - Dexamethasone and isatuximab-irfc †
 - Dexamethasone and selinexor
 - Dexamethasone and pomalidomide; **OR**
- Used as maintenance therapy for symptomatic disease in transplant candidates; **AND**
 - Used in combination with lenalidomide; **AND**
 - Used after response to primary myeloma therapy; **OR**

- Used for response or stable disease following an autologous hematopoietic cell transplant (HCT); **OR**
- Used for response or stable disease following a tandem autologous or allogeneic HCT for high risk* patients

**High-risk as defined by the Revised International Staging System for Multiple Myeloma is the presence of del(17p) and/or translocation t(4;14) and/or translocation t(14;16). This is not an all-inclusive list. Refer to the NCCN Multiple Myeloma Guidelines for additional risk factors.*

Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma ‡^{2,5,18,21,27e-31e,33e,43e}

- Used in combination with rituximab and dexamethasone (CaRD regimen); **AND**
 - Used as primary therapy

Systemic Light Chain Amyloidosis ‡^{2,30,31,38,39, 53e-67e}

- Patient has relapsed or refractory disease; **AND**
- Patient has non-cardiac disease; **AND**
 - Used as a single agent; **OR**
 - Used in combination with dexamethasone

Preferred therapies and recommendations are determined by review of clinical evidence. NCCN category of recommendation is taken into account as a component of this review. Regimens deemed equally efficacious (i.e., those having the same NCCN categorization) are considered to be therapeutically equivalent.

† FDA Approved Indication(s); ‡ Compendia Recommended Indication(s); ◊ Orphan Drug

IV. Renewal Criteria^{1,2}

Coverage may be renewed based upon the following criteria:

- Patient continues to meet the indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. identified in section III; **AND**
- Disease response with treatment as defined by stabilization of disease or decrease in size of tumor or tumor spread; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: cardiac toxicity (e.g., CHF, pulmonary edema, decreased ejection fraction, cardiomyopathy, myocardial ischemia, myocardial infarction, etc.), pulmonary toxicity (e.g., acute respiratory distress syndrome [ARDS], acute respiratory failure, etc.), pulmonary hypertension, dyspnea, severe infusion related reactions, tumor lysis syndrome (TLS), thrombocytopenia, hepatic toxicity/failure, thrombotic microangiopathy (including thrombotic thrombocytopenic

purpura/hemolytic uremic syndrome [TTP/HUS]), acute renal failure, severe hypertension, posterior reversible encephalopathy syndrome (PRES), venous thromboembolic events (e.g., deep venous thrombosis, pulmonary embolism, etc.), hemorrhage, progressive multifocal leukoencephalopathy (PML), etc.; **AND**

Multiple Myeloma ^{1,12,27,32,36}

- Combination therapy with lenalidomide and dexamethasone may be renewed up to a maximum of eighteen (18) 28-day treatment cycles.
- Combination therapy with daratumumab, lenalidomide, and dexamethasone may be renewed up to a maximum of eight (8) 28-day treatment cycles.
- Combination therapy with lenalidomide as maintenance therapy may be renewed up to a maximum of 2 years of therapy

Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma ^{5,21}

- Combination therapy with rituximab and dexamethasone (CaRD regimen) may be renewed up to a maximum of six (6) 21-day induction treatment cycles and eight (8) 56-day maintenance treatment cycles.

V. **Dosage/Administration** ^{1,5,7,9,12,20-22,24-28,30,32-36,38-39}

Indication	Dose*
Multiple Myeloma (primary therapy OR disease relapse ≥6 months following primary induction therapy with the same regimen)	<p><u>Combination with daratumumab, lenalidomide and dexamethasone (Dara-KRd)</u></p> <p>20/56 regimen:</p> <ul style="list-style-type: none"> – Cycle 1: 20 mg/m² on day 1; if tolerated, increase to 56 mg/m² on days 8 and 15 of a 28-day treatment cycle – Cycles 2 through 8: 56 mg/m² on days 1, 8, and 15 of a 28-day treatment cycle <p><u>Combination with lenalidomide and dexamethasone (KRd)</u></p> <p>20/36 regimen:</p> <ul style="list-style-type: none"> – Cycle 1: 20 mg/m² on days 1 and 2; if tolerated, increase to 36 mg/m² days 8, 9, 15, and 16 of a 28-day treatment cycle – Cycles 2 through 8: 36 mg/m² days 1, 2, 8, 9, 15, and 16 of a 28-day treatment cycle – Cycles 9 through 18: 36 mg/m² days 1, 2, 15, and 16 of a 28-day treatment cycle <p><u>Combination with cyclophosphamide and dexamethasone (KCd)</u></p> <p>20/36 regimen:</p> <ul style="list-style-type: none"> – Cycle 1: 20 mg/m² on days 1 and 2; if tolerated, increase to 36 mg/m² days 8, 9, 15, and 16 of a 28-day treatment cycle – Cycles 2 through 9: 36 mg/m² days 1, 2, 8, 9, 15, and 16 of a 28-day treatment cycle – Cycle 10 and beyond: 36 mg/m² on days 1, 2, 15, and 16 of a 28-day treatment cycle; continue until disease progression or unacceptable toxicity <p>20/70 regimen:</p> <ul style="list-style-type: none"> – Cycle 1: 20 mg/m² on day 1; if tolerated, increase to 70 mg/m² days 8 and 15 of a 28-day treatment cycle – Cycles 2 through 9: 70 mg/m² days 1, 8, and 15 of a 28-day treatment cycle – Cycle 10 and beyond: 70 mg/m² on days 1 and 15 of a 28-day treatment cycle; continue until disease progression or unacceptable toxicity

<p>Multiple Myeloma (relapsed, progressive, or refractory disease)</p>	<p><u>Single agent</u></p> <p>20/27 regimen:</p> <ul style="list-style-type: none"> - Cycle 1: 20 mg/m² on days 1 and 2; if tolerated, increase to 27 mg/m² on days 8, 9, 15, and 16 of a 28-day treatment cycle - Cycles 2 through 12: 27 mg/m² on days 1, 2, 8, 9, 15, and 16 of a 28-day treatment cycle - Cycle 13 and beyond: 27 mg/m² on days 1, 2, 15, and 16 of a 28-day treatment cycle; continue until disease progression or unacceptable toxicity <p>20/56 regimen:</p> <ul style="list-style-type: none"> - Cycle 1: 20 mg/m² on days 1 and 2; if tolerated, increase to 56 mg/m² on days 8, 9, 15, and 16 of a 28-day treatment cycle. - Cycles 2 through 12: 56 mg/m² on days 1, 2, 8, 9, 15, and 16 of a 28-day treatment cycle - Cycle 13 and beyond: 56 mg/m² on days 1, 2, 15, and 16 of a 28-day treatment cycle; continue until disease progression or unacceptable toxicity <p><u>Combination with lenalidomide and dexamethasone (KRd)</u></p> <p>20/27 regimen:</p> <ul style="list-style-type: none"> - Cycle 1: 20 mg/m² on days 1 and 2; if tolerated, increase to 27 mg/m² on days 8, 9, 15, and 16 of a 28-day treatment cycle - Cycles 2 through 12: 27 mg/m² on days 1, 2, 8, 9, 15, and 16 of a 28-day treatment cycle - Cycles 13 through 18: 27 mg/m² on days 1, 2, 15, and 16 of a 28-day treatment cycle; beginning with cycle 19, lenalidomide and dexamethasone may be continued (until disease progression or unacceptable toxicity) without carfilzomib <p><u>Combination with dexamethasone (Kd)</u></p> <p>20/56 regimen:</p> <ul style="list-style-type: none"> - Cycle 1: 20 mg/m² on days 1 and 2; if tolerated, increase to 56 mg/m² on days 8, 9, 15, and 16 of a 28-day treatment cycle - Cycle 2 and beyond: 56 mg/m² on days 1, 2, 8, 9, 15, and 16 of a 28-day treatment cycle; continue until disease progression or unacceptable toxicity <p>20/70 regimen:</p> <ul style="list-style-type: none"> - Cycle 1: 20 mg/m² on day 1; if tolerated, increase to 70 mg/m² on day 8 and 15 of a 28-day treatment cycle - Cycle 2 and beyond: 70 mg/m² on days 1, 8, and 15 of a 28-day treatment cycle; continue until disease progression or unacceptable toxicity <p><u>Combination with daratumumab (or daratumumab and hyaluronidase-fihj) and dexamethasone (DKd)</u></p> <p>20/56 regimen:</p> <ul style="list-style-type: none"> - Cycle 1: 20 mg/m² on days 1 and 2; if tolerated, increase to 56 mg/m² on days 8, 9, 15 and 16 of a 28-day treatment cycle - Cycle 2 and beyond: 56 mg/m² on days 1, 2, 8, 9, 15, and 16 of a 28-day treatment cycle; continue until disease progression or unacceptable toxicity <p>20/70 regimen:</p> <ul style="list-style-type: none"> - Cycle 1: 20 mg/m² on day 1; if tolerated, increase to 70 mg/m² on day 8 and 15 of a 28-day treatment cycle - Cycle 2 and beyond: 70 mg/m² on days 1, 8, and 15 of a 28-day treatment cycle; continue until disease progression or unacceptable toxicity <p><u>Combination with cyclophosphamide and dexamethasone (KCd)</u></p> <p>20/36 regimen:</p> <p>Induction</p> <ul style="list-style-type: none"> - Cycle 1: 20 mg/m² on days 1 and 2; if tolerated, increase to 36 mg/m² days 8, 9, 15, and 16 of a 28-day treatment cycle - Cycles 2 through 6: 36 mg/m² days 1, 2, 8, 9, 15, and 16 of a 28-day treatment cycle <p>Maintenance</p>
--	--

	<ul style="list-style-type: none"> - Cycles 7 through 12: 36 mg/m² on days 1, 2, 15, and 16 of a 28-day treatment cycle - Cycle 13 and beyond: 36 mg/m² on days 1 and 2 of a 28-day treatment cycle; continue until disease progression or unacceptable toxicity <p><u>Combination with isatuximab-irfc and dexamethasone (Isa-Kd)</u></p> <p>20/56 regimen:</p> <ul style="list-style-type: none"> - Cycle 1: 20 mg/m² on days 1 and 2; if tolerated, increase to 56 mg/m² on days 8, 9, 15 and 16 of a 28-day treatment cycle - Cycle 2 and beyond: 56 mg/m² on days 1, 2, 8, 9, 15, and 16 of a 28-day treatment cycle; continue until disease progression or unacceptable toxicity <p><u>Combination with selinexor and dexamethasone (XKd)</u></p> <p>20/56 regimen:</p> <ul style="list-style-type: none"> - Cycle 1: 20 mg/m² on day 1; if tolerated, increase to 56 mg/m² on days 8 and 15 of a 28-day treatment cycle - Cycle 2 and beyond: 56 mg/m² on days 1, 8, and 15 of a 28-day treatment cycle; continue until disease progression or unacceptable toxicity <p><u>Combination with pomalidomide and dexamethasone (KPd)</u></p> <p>20/27 regimen:</p> <ul style="list-style-type: none"> - Cycle 1: 20 mg/m² on days 1 and 2; if tolerated, increase to 27 mg/m² on days 8, 9, 15, and 16 of a 28-day treatment cycle - Cycles 2 through 6: 27 mg/m² on days 1, 2, 8, 9, 15, and 16 of a 28-day treatment cycle - Cycle 7 and beyond: 27 mg/m² on days 1, 2, 15, and 16 of a 28-day treatment cycle; continue until disease progression or unacceptable toxicity - NOTE: If disease progression occurs while on maintenance dosing, resume full dosing of 27 mg/m² on days 1, 2, 8, 9, 15, and 16 of a 28-day treatment cycle <p>20/36 regimen:</p> <ul style="list-style-type: none"> - Cycle 1: 20 mg/m² on days 1 and 2; if tolerated, increase to 36 mg/m² days 8, 9, 15, and 16 of a 28-day treatment cycle - Cycles 2 through 8: 36 mg/m² days 1, 2, 8, 9, 15, and 16 of a 28-day treatment cycle - Cycle 9 and beyond: 36 mg/m² days 1, 2, 15, and 16 of a 28-day treatment cycle; continue until disease progression or unacceptable toxicity
<p>Multiple Myeloma (relapsed or refractory disease after 3 prior therapies)</p>	<p><u>Combination with bendamustine and dexamethasone</u></p> <p>20/27 regimen:</p> <ul style="list-style-type: none"> - Cycle 1: 20 mg/m² on days 1 and 2; if tolerated, increase to 27 mg/m² on days 8, 9, 15, and 16 of a 28-day treatment cycle - Cycles 2 through 8: 27 mg/m² on days 1, 2, 8, 9, 15, and 16 of a 28-day treatment cycle - Cycle 9 and beyond: 27 mg/m² on days 1, 2, 15, and 16 of a 28-day treatment cycle; continue until disease progression or unacceptable toxicity
<p>Multiple Myeloma (maintenance therapy)</p>	<p><u>Combination with lenalidomide</u></p> <ul style="list-style-type: none"> - 36 mg/m² days 1, 2, 15, and 16 of a 28-day treatment cycle for up to 2 years - NOTE: lenalidomide may be continued until disease progression or unacceptable toxicity without carfilzomib
<p>Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma</p>	<p><u>CaRD regimen (carfilzomib, rituximab, dexamethasone)</u></p> <p>Induction</p> <ul style="list-style-type: none"> - Cycle 1: 20 mg/m² on days 1, 2, 8 and 9 of a 21-day treatment cycle - Cycles 2 through 6: 36 mg/m² on days 1, 2, 8 and 9 of a 21-day treatment; begin maintenance 8 weeks later <p>Maintenance</p> <ul style="list-style-type: none"> - 36 mg/m² on days 1 and 2 every 8 weeks for 8 cycles

Systemic Light Chain Amyloidosis	<p><u>Single agent or combination with dexamethasone</u></p> <p><u>20/27/56 regimen</u></p> <ul style="list-style-type: none"> - Cycle 1: 20 mg/m² on day 1; if tolerated, increase to 27 mg/m² days 8 and 15 of a 28-day treatment cycle - Cycle 2 and beyond: up to 56 mg/m² days 1, 8, and 15 of a 28-day treatment cycle <p><u>20/36 regimen</u></p> <ul style="list-style-type: none"> - Cycle 1: 20 mg/m² on days 1 and 2; if tolerated, increase to 36 mg/m² days 8, 9, 15, 16 of a 28-day treatment cycle - Cycles 2 through 8: 36 mg/m² days 1, 2, 8, 9, 15, and 16 of a 28-day treatment cycle - Cycles 9 and beyond: 36 mg/m² days 1, 2, 15, and 16 of a 28-day treatment cycle
<p><i>*Note: For patients with body surface area (BSA) of 2.2 m² or less, calculate the Kyprolis dose using actual BSA. Dose adjustments do not need to be made for weight changes of 20% or less. For patients with a BSA greater than 2.2 m², calculate the Kyprolis dose using a BSA of 2.2 m².</i></p>	

VI. Billing Code/Availability Information

HCPCS Code:

- J9047 – Injection, carfilzomib, 1 mg; 1mg = 1 billable unit

NDC(s):

- Kyprolis 10 mg single-dose vial for injection: 76075-0103-xx
- Kyprolis 30 mg single-dose vial for injection: 76075-0102-xx
- Kyprolis 60 mg single-dose vial for injection: 76075-0101-xx

VII. References (STANDARD)

1. Kyprolis [package insert]. Thousand Oaks, CA; Onyx Pharmaceuticals, Inc.; June 2022. Accessed December 2023.
2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Carfilzomib. National Comprehensive Cancer Network, 2023. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed December 2023.
3. BGM Durie, J-L Harousseau, J S Miguel, et al on behalf of the International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia. 2006 Sep; 20(9):1467-73.
4. Dimopoulos MA, Kastritis E, Owen RG, et al. Treatment recommendations for patients with Waldenström's macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood. 2014; 124(9):1404–1411.
5. Treon SP, Tripsas CK, Meid K, et al. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia. Blood. 2014;124(4):503–510.

6. UpToDate. Hudson (OH): Lexicomp Inc.: Carfilzomib: Drug information. Topic 86042 Version 263.0, 2023 Accessed December 2023.
7. Shah JJ, Stadtmauer EA, Abonour R, et al. Carfilzomib, pomalidomide and dexamethasone for relapsed or refractory myeloma. *Blood* 2015; 126: 2284-2290.
8. Berdeja JG, Hart LL, Mace JR, et al. Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma. *Haematologica* 2015; 100: 670-676.
9. Bringhen S, Petrucci MT, Larocca A, et al. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. *Blood*. 2014 Jul 3;124(1):63-9.
10. Moreau P, Mateos MV, Berenson JR, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. *Lancet Oncol* 2018;19(7):953-964.
11. Chari A, Martinez-Lopez J, Mateos MV, et al. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. *Blood* 2019. Aug 1;134(5):421-431. doi: 10.1182/blood.2019000722. Epub 2019 May 21.
12. Mikhael JR, Reeder CB, Libby EN, et al. Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma. *Br J Haematol*. 2015 Apr; 169(2): 219–227. Published online 2015 Feb 13.
13. Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. *N Engl J Med*. 2015 Jan 8;372(2):142-52. doi: 10.1056/NEJMoa1411321. Epub 2014 Dec 6.
14. Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. *Lancet Oncol*. 2016 Jan;17(1):27-38. doi: 10.1016/S1470-2045(15)00464-7. Epub 2015 Dec 5.
15. Papadopoulos KP, Siegel DS, Vesole DH, et al. Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma. *J Clin Oncol*. 2015 Mar 1;33(7):732-9. doi: 10.1200/JCO.2013.52.3522. Epub 2014 Sep 15.
16. Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. *Blood*. 2012 Oct 4;120(14):2817-25. doi: 10.1182/blood-2012-05-425934. Epub 2012 Jul 25.
17. Vij R, Wang M, Kaufman JL, et al. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. *Blood*. 2012 Jun 14;119(24):5661-70. doi: 10.1182/blood-2012-03-414359. Epub 2012 May 3.

18. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024. National Comprehensive Cancer Network, 2023. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org. Accessed December 2023.
19. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Multiple Myeloma, Version 2.2024. National Comprehensive Cancer Network, 2023. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org. Accessed December 2023.
20. Rosenbaum CA, Stephens LA, Kukreti V, et al. Phase ½ study of carfilzomib, pomalidomide, and dexamethasone (Kpd) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): A Multiple Myeloma Research Consortium multicenter study. DOI: 10.1200/JCO.2016.34.15_suppl.8007 *Journal of Clinical Oncology* 34, no. 15_suppl (May 20, 2016) 8007-8007.
21. Meid K, Dubeau T, Severns P, et al. Long-Term Follow-up of a Prospective Clinical Trial of Carfilzomib, Rituximab and Dexamethasone (CaRD) in Waldenstrom’s Macroglobulinemia. *Blood* 2017; 130:2772-2772.
22. Yong K, Brown S, Hinsley S, et al. Carfilzomib, cyclophosphamide and dexamethasone is well tolerated in patients with relapsed/refractory multiple myeloma who have received one prior regimen. 2015; 126:1840.
23. Dimopoulos M, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. *Lancet*. 2020;396(10245):186-197.
24. Jakubowiak AJ, Dytfeld D, Griffith KA, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. *Blood*. 2012 Aug 30;120(9):1801-9.
25. Korde N, Zingone A, Kwok M, et al. Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and Dexamethasone (CRd) in Newly Diagnosed Multiple Myeloma (MM) Patients. *Blood*. 2012 Nov 12;120(21):732.
26. Korde N, Zingone A, Kwok ML, et al. Phase II Clinical and Correlative Study Of Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Extended Dosing (CRD-R) Induces High Rates Of MRD Negativity In Newly Diagnosed Multiple Myeloma (MM) Patients. *Blood*. 2013 Nov 15;122(21):538.

27. Zimmerman T, Raje NS, Reece D, et al. Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM). *Blood*. 2016 Dec 2;128(22):675.
28. Yong K, Hinsley S, De Tute, RM, et al. Maintenance with Carfilzomib Following Carfilzomib, Cyclophosphamide and Dexamethasone at First Relapse or Primary Refractory Multiple Myeloma (MM) on the Phase 2 Muk Five Study: Effect on Minimal Residual Disease. *Blood*. 2018 Nov 29;132(1):802.
29. Moreau P, Dimopoulos MA, Yong K, et al. Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design. *Future Oncol*. 2020 Jan;16(2):4347-4358. Doi: 10.2217/fo-2019-0431.
30. Manwani R, Mahmood S, Sachchithanatham S, et al. Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy. *Br J Haematol* 2019 Dec;187(5):638-641.doi: 10.1111/bjh.16122. Epub 2019 Aug 6.
31. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®]) for Systemic Light Chain Amyloidosis, Version 1.2024. National Comprehensive Cancer Network, 2023. NATIONAL COMPREHENSIVE CANCER NETWORK[®], NCCN[®], and NCCN GUIDELINES[®] are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed December 2023.
32. Landren O, Hulcrantz M, Diamond B, et al. Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial. *JAMA Oncol*. 2021 Jun 1;7(6):862-868. doi: 10.1001/jamaoncol.2021.0611
33. Bringhen S, D'Agostino M, De Paoli L, et al. Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma. *Leukemia*. 2018 Apr;32(4):979-985. doi: 10.1038/leu.2017.327.
34. Gasparetto C, Lipe B, Tuchman S, et al. Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed/refractory multiple myeloma (MM). DOI: 10.1200/JCO.2020.38.15_suppl.8530 *Journal of Clinical Oncology* 38, no. 15_suppl (May 20, 2020) 8530-8530.
35. Gay F, Günther A, Offidani M, et al. Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network. *Cancer*. 2021 Sep 15;127(18):3413-3421. doi: 10.1002/cncr.33647
36. Gay F, Musto P, Scalabrini D, et al. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a

randomized, open-label, phase 2 trial. *Lancet Oncol.* 2021 Dec;22(12):1705-1720. doi: 10.1016/S1470-2045(21)00535-0. Epub 2021 Nov 11.

37. Moreau P, Dimopoulos MA, Mikhael J, et al.; IKEMA study group. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. *Lancet.* 2021 Jun 19;397(10292):2361-2371. doi: 10.1016/S0140-6736(21)00592-4.
38. Cohen AD, Landau H, Scott EC, et al. Safety and efficacy of carfilzomib (CFZ) in previously-treated systemic light-chain (AL) amyloidosis. *Blood* 2016;128:645-645. Doi: 10.1182/blood.V128.22.645.645.
39. Costa LJ, Davies FE, Monohan GP, et al. Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. *Blood Adv.* 2021 Oct 12;5(19):3748-3759. doi: 10.1182/bloodadvances.2020004146.

VIII. References (ENHANCED)

- 1e. Durie BG, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. *Lancet.* 2016;389(10068):519-527.
- 2e. Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. *J Clin Oncol.* 2012 Aug 20;30(24):2946-55. doi: 10.1200/JCO.2011.39.6820.
- 3e. Moreau P, Hulin C, Macro M, et al. VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. *Blood.* 2016 May 26;127(21):2569-74. doi: 10.1182/blood-2016-01-693580.
- 4e. Kumar S, Flinn I, Richardson PG, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. *Blood.* 2012 May 10;119(19):4375-82. doi: 10.1182/blood-2011-11-395749.
- 5e. Zimmerman T, Raje NS, Reece D, et al. Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM). *Blood.* 2016; 128:675.
- 6e. Kumar SK, Lacy MQ, Hayman SR, et al. Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial. *Am J Hematol.* 2011;86(8):640-5.
- 7e. Barlogie B, Anaissie E, van Rhee F, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. *Br J Haematol.* 2007 Jul;138(2):176-85.

- 8e. Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. *N Engl J Med* 2018; 378:518-528.
- 9e. Zepeda VH, Duggan P, Neri PE, Bahlis NJ. Cyclophosphamide, Bortezomib and Dexamethasone (CyBORD) Is a Feasible and Active Regimen for Non-Transplant Eligible Multiple Myeloma Patients. *Blood*. 2014; 124:5751.
- 10e. Jakubowiak AJ, Dytfeld D, Griffith KA, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. *Blood*. 2012;120(9):1801-9.
- 11e. Dytfeld D, Jasieles J, Griffith KA, et al. Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma. *Haematologica*. 2014;99(9):e162-4.
- 12e. Kumar SK, Berdeja JG, Niesvizky R, et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. *Lancet Oncol*. 2014 Dec;15(13):1503-12. doi: 10.1016/S1470-2045(14)71125-8.
- 13e. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. *Lancet Oncol*. 2009;11(1):29-37.
- 14e. Zonder JA, Crowley J, Hussein MA, et al. Superiority of Lenalidomide (Len) Plus High-Dose Dexamethasone (HD) Compared to HD Alone as Treatment of Newly-Diagnosed Multiple Myeloma (NDMM): Results of the Randomized, Double-Blinded, Placebo-Controlled SWOG Trial S0232. *Blood*. 2007; 110:77.
- 15e. Siegel DS, Dimopoulos MA, Ludwig H, et al. Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. *J Clin Oncol*. 2018 Mar 10;36(8):728-734.
- 16e. Dimopoulos MA, Goldschmidt H, Niesvizky R, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. *Lancet Oncol*. 2017 Oct;18(10):1327-1337.
- 17e. Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. *N Engl J Med* 2016; 375:754-766.
- 18e. Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. *N Engl J Med* 2016; 375:1319-1331.
- 19e. Moreau P, Masszi T, Grzasko N, et al. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. *N Engl J Med* 2016; 374:1621-1634.
- 20e. Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. *N Engl J Med* 2015; 373:621-631.
- 21e. Lonial S, Richardson PG, Mateos MV, et al. ELOQUENT-2 update: Phase III study of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma

- (RRMM)—Identifying responders by subset analysis. *Journal of Clinical Oncology* 34, no. 15_suppl (May 2016) 8037-8037.
- 22e. Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. *Blood*. 2012;120(14):2817-25.
- 23e. Yong K, Hinsley S, Auner HW, et al. Carfilzomib, Cyclophosphamide and Dexamethasone (KCD) Versus Bortezomib, Cyclophosphamide and Dexamethasone (VCD) for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): First Final Analysis of the Phase 2 Muk Five Study. *Blood*. 2017; 130:835.
- 24e. San-Miguel JF, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. *Lancet Oncol*. 2014 Oct;15(11):1195-206.
- 25e. Richardson PG, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. *Blood*. 2016;127(6):713-21.
- 26e. Richardson PG, Jagannath S, Jakubowiak AJ, et al. Phase II Trial of Lenalidomide, Bortezomib, and Dexamethasone In Patients (pts) with Relapsed and Relapsed/Refractory Multiple Myeloma (MM): Updated Efficacy and Safety Data After >2 Years of Follow-up. *Blood*. 2010; 116:3049.
- 27e. Dimopoulos MA, Tedeschi A, Trotman J, et al. Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia. *N Engl J Med* 2018; 378:2399-2410.
- 28e. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. *Lancet*. 2013 Apr 6;381(9873):1203-10.
- 29e. Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. *J Clin Oncol*. 2009;27(23):3830-5.
- 30e. Dimopoulos MA, García-Sanz R, Gavriatopoulou M, et al. Primary therapy of Waldenström macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). *Blood*. 2013; 122:3276-3282.
- 31e. Dimopoulos MA, Anagnostopoulos A, Kyrtsolis MC, et al. Primary Treatment of Waldenström Macroglobulinemia With Dexamethasone, Rituximab, and Cyclophosphamide. *Journal of Clinical Oncology* 2007 25:22, 3344-3349.
- 32e. Kastiris E, Gavriatopoulou M, Kyrtsolis MC, et al. Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study. *Blood*. 2015; 126:1392-1394.

- 33e. Paludo J, Abeykoon JP, Kumar S, et al. Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia. *Br J Haematol*. 2017 Oct;179(1):98-105.
- 34e. Facon T, Kumar S, Plesner T, et al. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. *N Engl J Med*. 2019 May 30;380(22):2104-2115. doi: 10.1056/NEJMoa1817249.
- 35e. Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-
- 36e. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial [published correction appears in *Lancet Oncol*. 2010 Jan;11(1):14]. *Lancet Oncol*. 2010;11(1):29–37. doi:10.1016/S1470-2045(09)70284-001.
- 37e. Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. *Lancet*. 2019 Jul 6;394(10192):29-38. doi: 10.1016/S0140-6736(19)31240-1. Epub 2019 Jun 3.
- 38e. Brown S, Hinsley S, Ballesteros M, et al. The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma. *BMC Hematol*. 2016;16:14. Published 2016 May 17. doi:10.1186/s12878-016-0053-9.
- 39e. Kumar SK, Jacobus SJ, Cohen AD, et al. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial [published online ahead of print, 2020 Aug 28]. *Lancet Oncol*. 2020;S1470-2045(20).
- 40e. Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. *Blood*. 2020 Aug 20;136(8):936-945. doi: 10.1182/blood.2020005288.
- 41e. Yimer H, Melear J, Faber E, et al. Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study. *Br J Haematol*. 2019;185(3):492-502. doi:10.1111/bjh.15806.
- 42e. Moreau P, Dimopoulos MA, Mikhael J, et al: Isatuximab plus carfilzomib and dexamethasone vs carfilzomib and dexamethasone in relapsed/refractory multiple myeloma (IKEMA): Interim analysis of a phase III, randomized, open-label study. EHA25 Virtual Congress. Abstract LB2603.

- 43e. Tam CS, LeBlond V, Novotny W, et al. A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia. *Future Oncol*. 2018 Sep;14(22):2229-2237. doi: 10.2217/fon-2018-0163. Epub 2018 Jun 5.
- 44e. Chen, Y., Gopalakrishnan, S.K., Ooi, M. et al. A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1). *Blood Cancer J*. 11, 150 (2021). <https://doi.org/10.1038/s41408-021-00544-x>
- 45e. Dimopoulos MA, Grosicki S, Jędrzejczak WW, et al. All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. *Eur J Cancer*. 2019 Jan;106:89-98. doi: 10.1016/j.ejca.2018.09.011.
- 46e. Yimer H, Melear J, Faber E, et al. Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study. *Br J Haematol*. 2019;185(3):492-502. Doi:10.1111/bjh.15806.
- 47e. Dimopoulos M, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. *Lancet*. 2020 Jul 18;396(10245):186-197. doi: 10.1016/S0140-6736(20)30734-0. Erratum in: *Lancet*. 2020 Aug 15;396(10249):466. PMID: 32682484.
- 48e. Gasparetto C, Schiller GJ, Tuchman SA, et al. Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients. *Br J Cancer*. 2022;126(5):718-725. doi:10.1038/s41416-021-01608-2
- 49e. Kumar SK, Buadi FK, LaPlant B, et al. Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. *Blood Cancer J*. 2018 Jul 30;8(8):70. doi: 10.1038/s41408-018-0106-3.
- 50e. Ioakimidis L, Patterson CJ, Hunter ZR, et al. Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemia. *Clin Lymphoma Myeloma*. 2009 Mar;9(1):62-6. doi: 10.3816/CLM.2009.n.016. PMID: 19362976.
- 51e. Castillo JJ, Meid K, Flynn CA, et al. Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up. *Blood Adv*. 2020 Aug 25;4(16):3952-3959.
- 52e. Gertz MA, Rue M, Blood E, Kaminer LS, Vesole DH, Greipp PR. Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). *Leuk Lymphoma*. 2004 Oct;45(10):2047-55.
- 53e. Jaccard A, Moreau P, Leblond V, et al. Myelome Autogreffe (MAG) and Intergroupe Francophone du Myelome (IFM) Intergroup. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. *N Engl J Med*. 2007 Sep 13;357(11):1083-93. doi: 10.1056/NEJMoa070484.
- 54e. Gasparetto C, Sanchorawala V, Snyder RM, et al. Use of melphalan (M)/dexamethasone (D)/bortezomib in AL amyloidosis. *J Clin Oncol* 2010; 28:Abstract 8024.

- 55e. Santhorawala V, Wright DG, Rosenzweig M, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. *Blood*. 2007 Jan 15;109(2):492-6. doi: 10.1182/blood-2006-07-030544.
- 56e. Palladini G, Russo P, Milani P, et al. A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. *Haematologica*. 2013 Mar;98(3):433-6. doi: 10.3324/haematol.2012.073593. Epub 2012 Sep 14.
- 57e. Dispenzieri A, Buadi F, Laumann K, et al. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. *Blood*. 2012;119(23):5397-5404. doi:10.1182/blood-2012-02-413161.
- 58e. Santhorawala V, Palladini G, Kukreti V, et al. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis [published correction appears in *Blood*. 2020 Mar 26;135(13):1071]. *Blood*. 2017;130(5):597-605. doi:10.1182/blood-2017-03-771220.
- 59e. Reece DE, Hegenbart U, Santhorawala V, et al. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. *Blood*. 2011 Jul 28;118(4):865-73. doi: 10.1182/blood-2011-02-334227.
- 60e. Santhorawala V, Sarosiek S, Schulman A, et al. Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study. *Blood*. 2020 Apr 30;135(18):1541-1547. doi: 10.1182/blood.2019004436.
- 61e. Roussel M, Merlini G, Chevret S, et al. A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis. *Blood*. 2020 Apr 30;135(18):1531-1540. doi: 10.1182/blood.2019004369.
- 62e. Kaufman GP, Schrier SL, Lafayette RA, et al. Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. *Blood*. 2017 Aug 17;130(7):900-902. doi: 10.1182/blood-2017-01-763599. Epub 2017 Jun 14.
- 63e. Dispenzieri A, Kastritis E, Wechalekar AD, et al. A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis. *Leukemia*. 2022 Jan;36(1):225-235. doi: 10.1038/s41375-021-01317-y. Epub 2021 Jun 24. PMID: 34168284; PMCID: PMC8727292.
- 64e. Lentzsch S, Lagos GG, Comenzo RL, et al. Bendamustine with dexamethasone in relapsed/refractory systemic light-chain amyloidosis: Results of a phase II study. *J Clin Oncol* 2020;38:1455-1462.
- 65e. Kastritis E, Wechalekar AD, Dimopoulos MA, et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. *J Clin Oncol* 2010;28:1031-1037.
- 66e. Cohen OC, Sharpley F, Gilmore JD, et al. Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light-chain amyloidosis. *Br J Haematol* 2020;189:643-649.
- 67e. Premkumar VJ, Lentzsch, Pan S, et al. Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis. *Blood Cancer J* 2021;11:10.

68e. Abuelgasim KA, Alherz N, Alhejazi A, Damlaj M. Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature. J Med Case Rep 2020;14:54. PMID: 34388020.

69e. Magellan Rx Management. Kyprolis Clinical Literature Review Analysis. Last updated December 2023. Accessed December 2023.

Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
C88.0	Waldenström macroglobulinemia
C90.00	Multiple myeloma not having achieved remission
C90.02	Multiple myeloma in relapse
C90.10	Plasma cell leukemia not having achieved remission
C90.12	Plasma cell leukemia in relapse
C90.20	Extramedullary plasmacytoma not having achieved remission
C90.22	Extramedullary plasmacytoma in relapse
C90.30	Solitary plasmacytoma not having achieved remission
C90.32	Solitary plasmacytoma in relapse
E85.3	Secondary systemic amyloidosis
E85.4	Organ-limited amyloidosis
E85.81	Light chain (AL) amyloidosis
E85.89	Other amyloidosis
E85.9	Amyloidosis, unspecified
Z85.79	Personal history of other malignant neoplasms of lymphoid, hematopoietic and related tissues

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

The preceding information is intended for non-Medicare coverage determinations. Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determinations (NCDs) and/or Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. Local Coverage Articles (LCAs) may also exist for claims payment purposes or to clarify benefit eligibility under Part B for drugs which may be self-administered. The following link may be used to search for NCD, LCD, or LCA documents: <https://www.cms.gov/medicare-coverage-database/search.aspx>. Additional indications, including any preceding information, may be applied at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/A

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)
6	MN, WI, IL	National Government Services, Inc. (NGS)
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto GBA, LLC
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA, LLC
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)
15	KY, OH	CGS Administrators, LLC